Identifying biomarkers for effective immunotherapy in kidney cancer
Official title: Tissue-based biomarkers of anti-PD-1-based therapy in metastatic renal cell carcinoma
Funded at Dana-Farber Cancer Inst · NIH-10847506 · Data updated 2026-11-12
This study is looking at how certain markers in tissue samples can help doctors figure out which patients with advanced kidney cancer are most likely to respond well to a specific immunotherapy treatment, so they can tailor the best care for each person.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $677,362 |
| NIH project number | 5R01CA266424-03 |
| Project ID | NIH-10847506 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic renal cell carcinoma who are considering or currently undergoing anti-PD-1 therapy.
✕Less likely to help
Patients with early-stage renal cell carcinoma or those who are not eligible for immunotherapy may not benefit from this research.
What this research studies
This research investigates how certain tissue-based biomarkers can predict the effectiveness of anti-PD-1 immunotherapy in patients with metastatic renal cell carcinoma (RCC). The team aims to understand the characteristics of T cells and the tumor microenvironment that influence treatment responses. By analyzing the expression of specific antigens and the presence of CD8+ T cells, the research seeks to identify which patients are most likely to benefit from this therapy. This could lead to more personalized treatment approaches for RCC patients.
Why it matters
Potential benefit: If successful, this research could help identify patients who are more likely to respond to immunotherapy, leading to improved treatment outcomes.
How similar studies have gone: Previous research has shown promising results in identifying biomarkers for immunotherapy responses in various cancers, suggesting that this approach may also be effective in RCC.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Choueiri, Toni — Dana-Farber Cancer Inst
- Study coordinator: Choueiri, Toni
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Biomarkers to predict and understand response to anti-PD-1 therapy in metastatic kidney cancer
This grant tests tissue clues like immune cells and tumor targets to figure out why some patients with metastatic kidney cancer respond to anti-PD-1 therapy while others do not.
-
Finding clues in tissue to improve kidney cancer treatment
This project looks for clues in tumor tissue to understand why some patients with advanced kidney cancer respond to immunotherapy and others do not.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.